TickerTalks
Browse all tickers →
TickerTalks›$LEGN
LELEGN

Legend Biotech Corporation

$LEGN·$4.1B·Biotechnology·Healthcare
$22.26-2.0%YTD+1.7%1Y-47.2%
Mentions · last 7 days
2026-07-11: 3 posts2026-07-12: 3 posts2026-07-13: 15 posts2026-07-14: 2 posts2026-07-15: 33 posts2026-07-16: 10 posts2026-07-17: 3 posts70+118%
Price updated 9h ago·X counts updated 9h ago
LELEGN
$LEGNLegend Biotech Corporation
$22.26-1.98%70 posts+118%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $LEGN, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Hinges on a big eventEvent coming upAI verdict · as of 2026-07-17

A known event soon (earnings, a ruling, etc.) will likely decide the next move.

Legend Biotech is the JNJ buyout speculation biotech with Carvykti — Aug 10 has to confirm the CAR-T ramp.

Legend Biotech is the specific CAR-T therapy developer whose Carvykti franchise for multiple myeloma is the specific commercial-and-buyout catalyst path. The stock is at 23% of its 52-week range with volume 80% above average signaling positioning.

Where the setup reads:

  • The buyout speculation is category-defining: JNJ speculation to strengthen its multiple-myeloma position with Legend as the specific target is the specific institutional-narrative catalyst.
  • The commercial economics are still transitioning: 55% gross margin at -12% operating margin means Carvykti is scaling but hasn't crossed into operating profitability — the specific ramp arriving is the whole thesis.
  • The tape confirms specific positioning: sitting 22% below the 50-day but 9% below the 200-day at 23% of the 52-week range with volume 80% above average — the specific pattern of a stock repositioning into a catalyst window.
  • The check is the specific $75-100 buyout speculation: without a specific offer, the tape is speculating on a specific transaction — meaning the print has to specifically deliver either commercial progress or M&A commentary.

Aug 10 earnings is the trigger. A number confirming Carvykti commercial ramp plus specific M&A-related commentary extends the leg materially; a soft Carvykti print with no M&A commentary is the specific setup for the buyout premium to compress.

Agrees with X sentimentX is bullish on the JNJ buyout speculation and the $75-100 target framing, and the setup is real — Carvykti is the specific commercial asset JNJ would target. The gap the corpus isn't sizing is that without a specific offer, buyout speculation compresses if the commercial ramp doesn't arrive.

What to watch: The Aug 10 print — Carvykti commercial ramp, M&A-related commentary, and any partnership commentary. Above-consensus Carvykti revenue plus M&A commentary extends the leg; a soft print compresses the buyout premium.

On the calendar: 2026-08-10 — Q2 earnings

X sentiment

What the X crowd is saying right now — descriptive, summarised from the day’s posts.

Bullish sentiment5 posts analyzed · as of 2026-07-04

Legend Biotech is one of the most-talked-about buyout targets at $75-$100. Bulls speculate JNJ could strengthen its position in the multiple myeloma market. Bear voices essentially absent.

Read the AI verdict + X sentiment for $LEGN

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Cell therapy biotech commercializing Carvykti (BCMA CAR-T) for multiple myeloma in partnership with J&J.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $LEGN.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $LEGN

Direct beneficiary — Cell therapy biotech commercializing Carvykti (BCMA CAR-T) for multiple myeloma in partnership with J&J; primary revenue lines track directly to the GLP-1 pipeline bifurcation and ADA oral formulation competition.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.9%YTD
+44.0%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-24.1How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-9.9%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
-11.9%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-3.9%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
5.3Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-24.9%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
55.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.4Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 12, 2026$-0.15$-0.02-650.0%
Q4 2025Mar 10, 2026$-0.08$-0.17+52.9%
Q3 2025Nov 12, 2025$-0.11$-0.13+15.4%
Q2 2025Aug 11, 2025$-0.34$-0.11-199.7%
Next earningsMon, Aug 10·consensus EPS $0.12

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$305.1M+56.4%42.3%-16.3%$-0.30$-111.3M
Q4 FY25$306.4M+64.3%59.7%-6.7%$-0.17$-126.6M
Q3 FY25$272.3M+70.0%57.7%-16.0%$-0.21$23.8M
Q2 FY25$255.1M+36.7%61.6%-8.6%$-0.68$-22.3M

Forward consensus

5-year forecast · up to 10 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$1.4B$1.4B – $1.5B$0.02-$0.64 – $1.3110
FY27$1.8B$1.5B – $1.9B$0.81$0.20 – $1.1710
FY28$2.1B$2.0B – $2.1B$1.34$1.02 – $1.6610
FY29$2.4B$2.2B – $2.6B$1.35$1.18 – $1.495
FY30$2.8B$2.5B – $3.0B$1.96$1.71 – $2.165

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.7×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.21%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.-24.0%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-11.3%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatMid float · 178.2M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.0% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β0.345-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.FilingActive offeringA shelf registration (S-3 / S-3ASR / S-1) or prospectus supplement (424B*) was filed in the last 90 days — the company is registered to (or actively) issuing new shares. Dilution risk.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

SellJun 30Casey Patrick JohnDirector6.0K sh$89KSellJun 25Ying HuangCEO5.6K sh$82KSellMar 25Ying HuangCEO9.9K sh$87K
+ 1 other (1 gift) in window

See when $LEGN insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

424B5Prospectus supplement (offering)Jun 18424B5
AI summary

Legend Biotech (LEGN) priced a follow-on ADS offering of 7,700,000 ADSs at $29.35 per ADS, raising approximately $226 million gross ($212.4 million net). Each ADS represents two ordinary shares. An overallotment option covers an additional 1,155,000 ADSs. Settlement was expected June 23, 2026. This secondary offering provides capital for Legend's CARVYKTI commercial scaling and pipeline programs.

424B5Prospectus supplement (offering)Jun 17424B5
AI summary

Legend Biotech Corporation (Nasdaq: LEGN, foreign private issuer) launched a $225 million preliminary public offering of American Depositary Shares (ADSs) via 424B5 on June 17, 2026, each ADS representing two ordinary shares at $0.0001 par value. The last reported ADS price on June 16, 2026 was $33.38; joint bookrunners are Morgan Stanley, Jefferies, Citigroup, and Deutsche Bank Securities. Underwriters received an option to purchase additional ADSs; final pricing, share count, and use of proceeds were not yet finalized at the preliminary stage. This is active dilution happening now — a $225M equity raise against a ~$3.4B market cap is material and will expand the ADS float upon final pricing.

3New insider — initial holdingsMar 183
3New insider — initial holdingsMar 183
3New insider — initial holdingsMar 183
3New insider — initial holdingsMar 183
3New insider — initial holdingsMar 183
3New insider — initial holdingsMar 183
+ 21 other (12 6-Ks · 6 3s · 1 F-6EF · 1 20-F) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Legend Biotech, Sleep Number And Other Big Stocks Moving Lower In Thursday's Pre-Market Sessionbenzinga.com·30d agoLegend Biotech Corporation Announces Pricing of Public Offeringglobenewswire.com·30d agoLegend Biotech Corporation Announces Proposed Public Offeringglobenewswire.com·31d agoLegend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphomaglobenewswire.com·33d agoLegend Biotech Establishes Clinical Proof-of-Concept for LB2501, a Potential First-in-Class In Vivo CD19/CD20 Dual-Targeting CAR-T, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphomaglobenewswire.com·34d ago

In themes

Explore the broader themes this ticker is being talked about under.

Trending on X

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$REGN$MRNA$AURA$SLS$RXRX
Voices on X · top 3 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport